Benchmarking health technology assessment agencies-methodological challenges and recommendations

被引:3
作者
Wang, Ting [1 ,2 ]
Lipska, Iga [1 ,2 ,3 ]
McAuslane, Neil [1 ]
Liberti, Lawrence [1 ]
Hovels, Anke [2 ]
Leufkens, Hubert [2 ]
机构
[1] Ctr Innovat Regulatory Sci, London, England
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[3] Natl Hlth Fund, Warsaw, Poland
关键词
Health technology assessment; Benchmarking tool; Medicines; RELATIVE EFFECTIVENESS ASSESSMENTS; HTA; DECISIONS; MEDICINES;
D O I
10.1017/S0266462320000598
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives The objectives of the study were to establish a benchmarking tool to collect metrics to enable increased clarity regarding the differences and similarities across health technology assessment (HTA) agencies, to assess performance within and across HTA agencies, identify areas in the HTA processes in which time is spent and to enable ongoing performance improvement. Methods Common steps and milestones in the HTA process were identified for meaningful benchmarking among agencies. A benchmarking tool consisting of eighty-six questions providing information on HTA agency organizational aspects and information on individual new medicine review timelines and outcomes was developed with the input of HTA agencies and validated in a pilot study. Data on 109 HTA reviews from five HTA agencies were analyzed to demonstrate the utility of this tool. Results This study developed an HTA benchmarking methodology, comparative metrics showed considerable differences among the median timelines from assessment and appraisal to final HTA recommendation for the five agencies included in this analysis; these results were interpreted in conjunction with agency characteristics. Conclusions It is feasible to find consensus among HTA agencies regarding the common milestones of the review process to map jurisdiction-specific processes against agreed metrics. Data on characteristics of agencies such as their scope and remit enabled results to be interpreted in the appropriate local context. This benchmarking tool has promising potential utility to improve the transparency of the review process and to facilitate both quality assurance and performance improvement in HTA agencies.
引用
收藏
页码:332 / 348
页数:17
相关论文
共 26 条
  • [11] A comparison of the drug review process at five international regulatory agencies
    Hirako, Mayu
    McAuslane, Neil
    Salek, Sam
    Anderson, Carly
    Walker, Stuart
    [J]. DRUG INFORMATION JOURNAL, 2007, 41 (03): : 291 - 308
  • [12] Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
    Kleijnen, S.
    Lipska, I.
    Alves, T. Leonardo
    Meijboom, K.
    Elsada, A.
    Vervoelgyi, V.
    d'Andon, A.
    Timoney, A.
    Leufkens, H. G.
    De Boer, A.
    Goettsch, W. G.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (09) : 1768 - 1775
  • [13] European collaboration on relative effectiveness assessments: What is needed to be successful?
    Kleijnen, Sarah
    Toenders, Wil
    de Groot, Folkert
    Huic, Mirjana
    George, Elisabeth
    Wieseler, Beate
    Pavlovic, Mira
    Bucsics, Anna
    Siviero, Paolo D.
    van der Graaff, Martin
    Rdzany, Rafal
    Kristensen, Finn Borlum
    Goettsch, Wim
    [J]. HEALTH POLICY, 2015, 119 (05) : 569 - 576
  • [14] STANDARDIZED REPORTING FOR RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS
    Kleijnen, Sarah
    Pasternack, Iris
    Van de Casteele, Marc
    Rossi, Bernardette
    Cangini, Agnese
    Di Bidino, Rossella
    Jelenc, Marjetka
    Abrishami, Payam
    Autti-Raemoe, Ilona
    Seyfried, Hans
    Wildbacher, Ingrid
    Goettsch, Wim G.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (05) : 488 - 496
  • [15] Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions
    Kleijnen, Sarah
    George, Elisabeth
    Goulden, Scott
    d'Andon, Anne
    Vitre, Pauline
    Osinska, Boguslawa
    Rdzany, Rafal
    Thirstrup, Steffen
    Corbacho, Belen
    Nagy, Bence Z.
    Leufkens, Hubert G.
    de Boer, Anthonius
    Goettsch, Wim G.
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 954 - 960
  • [16] Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
    Kristensen, Finn Borlum
    Husereau, Don
    Huic, Mirjana
    Drummond, Michael
    Berger, Marc L.
    Bond, Kenneth
    Augustovski, Federico
    Booth, Andrew
    Bridges, John F. P.
    Grimshaw, Jeremy
    IJzerman, Maarten J.
    Jonsson, Egon
    Ollendorf, Daniel A.
    Ruether, Alric
    Siebert, Uwe
    Sharma, Jitendar
    Wailoo, Allan
    [J]. VALUE IN HEALTH, 2019, 22 (01) : 13 - 20
  • [17] Health technology assessments: what do differing conclusions tell us?
    Kristensen, Finn Borlum
    Gerhardus, Ansgar
    [J]. BRITISH MEDICAL JOURNAL, 2010, 341 : 1029 - 1031
  • [18] Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA
    Kristensen, Finn Borlum
    Lampe, Kristian
    Chase, Deborah L.
    Lee-Robin, Sun Hae
    Wild, Claudia
    Moharra, Montse
    Garrido, Marcial Velasco
    Nielsen, Camilla Palmhoj
    Rottingen, John-Arne
    Neikter, Susanna Allgurin
    Bistrup, Marie Louise
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 1 - 8
  • [19] The HTA Core Model: A novel method for producing and reporting health technology assessments
    Lampe, Kristian
    Makela, Marjukka
    Garrido, Marcial Velasco
    Anttila, Heidi
    Autti-Ramo, Ilona
    Hicks, Nicholas J.
    Hofmann, Bjorn
    Koivisto, Juha
    Kunz, Regina
    Karki, Pia
    Malmivaara, Antti
    Meiesaar, Kersti
    Reiman-Mottonen, Paivi
    Norderhaug, Inger
    Pasternack, Iris
    Ruano-Ravina, Alberto
    Rasanen, Pirjo
    Saalasti-Koskinen, Ulla
    Saarni, Samuli I.
    Walin, Laura
    Kristensen, Finn Borlum
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 9 - 20
  • [20] THE ASSOCIATION BETWEEN EUROPEAN MEDICINES AGENCY APPROVAL AND HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATION
    Lipska, I
    Hoevels, A. M.
    McAuslane, N.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A455 - A455